Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: A case report Neurology

BMC Research Notes

Volumn 8, Issue 1, 2015, Pages

  Tzoulis, Charalampos ^a,b   Schwarzlmüller, Thomas ^a,b   Gjerde, Ivar Otto ^a   Softeland, Eirik ^a,b   Neckelmann, Gesche ^a   Biermann, Martin ^a,b   Haroche, Julien ^c,d   Straume, Oddbjorn ^a   Vintermyr, Olav Karsten ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

BRAF; Erdheim Chester; Histiocytosis; Spinal cord; Treatment; Tumor; Vemurafenib

Indexed keywords

INDOLE DERIVATIVE; SULFONAMIDE; VEMURAFENIB;

ADULT; CASE REPORT; ERDHEIM-CHESTER DISEASE; FEMALE; HUMAN; PATHOLOGY; SPINE; TREATMENT OUTCOME;

ADULT; ERDHEIM-CHESTER DISEASE; FEMALE; HUMANS; INDOLES; SPINE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84930077426     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-015-1135-7     Document Type: Article

References (19)

1. Lachenal F, Cotton F, Desmurs-Clavel H, Haroche J, Taillia H, Magy N, et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature. J Neurol. 2006;253(10):1267-77.
2. Arnaud L, Hervier B, Neel A, Hamidou MA, Kahn JE, Wechsler B, et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778-82.
3. Drier A, Haroche J, Savatovsky J, Godeneche G, Dormont D, Chiras J, et al. Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology. 2010;255(2):586-94.
4. Albayram S, Kizilkilic O, Zulfikar Z, Islak C, Kocer N. Spinal dural involvement in Erdheim-Chester disease: MRI findings. Neuroradiology. 2002;44(12):1004-7.
5. Curgunlu A, Karter Y, Ozturk A. Erdheim-Chester disease: a rare cause of paraplegia. Eur J Intern Med. 2003;14(1):53-5.
6. Takeuchi T, Sato M, Sonomura T, Itakura T. Erdheim-Chester disease associated with intramedullary spinal cord lesion. Br J Radiol. 2012;85(1011):e62-4.
7. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol. 2012;24(1):53-9.
8. Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116(20):4070-6.
9. Myra C, Sloper L, Tighe PJ, McIntosh RS, Stevens SE, Gregson RH, et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol. 2004;88(6):844-7.
10. Dagna L, Corti A, Langheim S, Guglielmi B, De Cobelli F, Doglioni C, et al. Tumor necrosis factor alpha as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol. 2012;30(28):e286-90.
11. Haroche J, Amoura Z, Charlotte F, Salvatierra J, Wechsler B, Graux C, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood. 2008;111(11):5413-5.
12. Chester W. Uber lipoidgranulomatose. Virchows Arch Pathol Anat. 1930;279:561-602.
13. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, Wechsler J, Brun B, Remy M, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore). 1996;75(3):157-69.
14. Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Toledano D, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients With BRAFV600E-Mutated Erdheim-Chester Disease. J Clin Oncol. 2015;33(5):411-8.
15. Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700-3.
16. Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495-500.
17. Tzoulis C, Gjerde IO, Softeland E, Neckelmann G, Strom E, Vintermyr OK, et al. Erdheim-Chester disease presenting with an intramedullary spinal cord lesion. J Neurol. 2012;259(10):2240-2.
18. Berget E, Helgeland L, Molven A, Vintermyr OK. Detection of clonality in follicular lymphoma using formalin-fixed, paraffin-embedded tissue samples and BIOMED-2 immunoglobulin primers. J Clin Pathol. 2011;64(1):37-41.
19. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323-32.